New interim data demonstrate Sandoz proposed biosimilar rituximab has equivalent efficacy to reference product

  • ASSIST-FL trial demonstrates equivalent safety, efficacy, pharmacokinetics and pharmacodynamics of Sandoz proposed biosimilar rituximab (GP2013) to the reference product[1]
  • Interim data in over 600 adults show potential of GP2013 as an alternative rituximab[1]
  • Sandoz proposed biosimilar rituximab is the company’s first monoclonal antibody candidate

Holzkirchen, December 5, 2016 – Sandoz, a Novartis division, and the pioneer and global leader in biosimilars, today announced data from the ASSIST-FL trial. The confirmatory safety and efficacy …

/by